FDA approves intramuscular administration for peginterferon beta-1a in MSFebruary 3, 2021Multiple Sclerosis
Is the EDSS an adequate outcome measure in secondary progressive MS trials?January 29, 2021Multiple Sclerosis
Physicians react: Doctors worry about patients reading their clinical notesJanuary 11, 2021Multiple Sclerosis
RRMS: Natalizumab improves work ability during first year of treatmentDecember 18, 2020Multiple Sclerosis
BTK Inhibitors: Researchers Eye Next-Generation Treatment Options for MSDecember 14, 2020Multiple Sclerosis
Natalizumab superior to fingolimod for active relapsing-remitting MSDecember 7, 2020Multiple Sclerosis
PPMS: Sustained benefit of ocrelizumab treatment on disease progressionDecember 7, 2020Multiple Sclerosis
